Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those with Type 2 Diabetes. This combination significantly outperforms FIB-4 and LSM, identifying twice as many patients with advanced fibrosis. It offers a promising non-invasive, upfront screening method, especially for those in FIB-4’s indeterminate zone.